Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209676 · ClinicalTrials.gov registry record · Early Phase 1
IMCgp100 in Advanced Unresectable Melanoma
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT01209676: Completed Early Phase 1 study, sponsored by University of Pennsylvania.
NCT01209676 is a Early Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209676, a Early Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with advanced unresectable melanoma to assess the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in the setting of advanced unresectable melanoma. Six patients will be enrolled to complete the study over approximately 12-15 months.
Primary Outcome
To determine the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in the setting of advanced unresectable melanoma. Tumor Lesions, peripheral blood pre- and post-injection will be used to determine the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in the setting of advanced unresectable melanoma
Interventions
- DRUG IMCgp100 injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-09 |
| Phase | Early Phase 1 |
What the finished NCT01209676 record still lists
NCT01209676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which IMCgp100 injection is the first listed.
NCT01209676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01209676 about?
NCT01209676 is a clinical study titled "IMCgp100 in Advanced Unresectable Melanoma". A phase 0, exploratory study of the pharmacodynamics of a single intratumoral dose of IMCgp100, a monoclonal T cell receptor anti-CD3 scFv fusion protein, in subjects with advanced unresectable melanoma to assess the safety and pharmacodynamic properties of single intratumoral doses of IMCgp100 in t...
What is the current status of trial NCT01209676?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2010-09.
What interventions are being tested in trial NCT01209676?
The interventions under investigation include: IMCgp100 injection (DRUG).
Who is sponsoring clinical trial NCT01209676?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01209676's enrollment target sits among peer trials
1 1985th of 2000 the lowest of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia